ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,616.33
0.64%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Jazz Pharmaceuticals PLC (JAZZ)

  7. Jazz Pharmaceuticals PLC (JAZZ) Noticias

JAZZ Jazz Pharmaceuticals PLC

112.91
0.21 (0.19%)
14 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Jazz Pharmaceuticals PLC JAZZ NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.21 0.19% 112.91 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
112.32 111.43 113.10 112.91 112.70
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
14/6/202415:12EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
14/6/202415:11EDGAR2Form DEF 14A - Other definitive proxy statements
11/6/202419:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202415:44EDGAR2Form 144 - Report of proposed sale of securities
03/6/202415:28EDGAR2Form PRE 14A - Other preliminary proxy statements
01/6/202407:05PRNUSJazz Pharmaceuticals Presents Overall Survival and Longer..
31/5/202416:01EDGAR2Form 8-K - Current report
30/5/202406:30PRNUSJazz Pharmaceuticals Showcases Pioneering Research in Sleep..
29/5/202415:15PRNUSJazz Pharmaceuticals to Participate in Upcoming June..
29/5/202406:45PRNUSZanidatamab Granted Priority Review for HER2-Positive..
22/5/202407:00PRNUSJazz Pharmaceuticals Announces Collaboration with Life..
07/5/202416:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/5/202415:10PRNUSJazz Pharmaceuticals to Participate in the BofA Securities..
01/5/202415:05PRNUSJazz Pharmaceuticals Announces First Quarter 2024 Financial..
24/4/202415:05PRNUSJazz Pharmaceuticals to Present Data Across Growing Oncology..
17/4/202415:15PRNUSJazz Pharmaceuticals to Report 2024 First Quarter Financial..
10/4/202406:45PRNUSJazz Pharmaceuticals to Showcase Expansive Neuroscience..
02/4/202406:30PRNUSJazz Pharmaceuticals Completes Zanidatamab Biologics License..
12/3/202415:15PRNUSJazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on..
08/3/202417:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202420:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202420:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202420:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202420:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202417:09EDGAR2Form 144 - Report of proposed sale of securities
05/3/202418:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:14EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/3/202414:11EDGAR2Form 144 - Report of proposed sale of securities
28/2/202415:06EDGAR2Form 8-K - Current report
28/2/202415:05PRNUSJazz Pharmaceuticals Announces Full Year and Fourth Quarter..
27/2/202406:45EDGAR2Form 8-K - Current report
27/2/202406:45PRNUSJazz Pharmaceuticals Appoints Patrick Kennedy to its Board..
21/2/202406:46EDGAR2Form 8-K - Current report
21/2/202406:45PRNUSJazz Pharmaceuticals Appoints Philip Johnson as Chief..
20/2/202415:15PRNUSJazz Pharmaceuticals to Participate in Upcoming March..
14/2/202415:15PRNUSJazz Pharmaceuticals to Report 2023 Full Year and Fourth..
07/2/202401:00PRNUSJazz Pharmaceuticals Enters Definitive Agreement with Redx..
25/1/202416:01EDGAR2Form 8-K - Current report
24/1/202408:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/1/202417:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202417:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202417:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202417:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
JAZZ
Jazz Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados